| Zeit | Aktuelle Nachrichten | ||
|---|---|---|---|
| 17:46 | QuantumCell commits $2.2bn on AlzeCure's Alzheimer's platform | ||
| 16:46 | Sanofi aims for Nexviazyme approval in younger Pompe disease patients | ||
| 13:46 | Anthropic debuts AI-driven pharma R&D tool, Claude Science | ||
| 12:46 | Medical journal retracts Tavneos pivotal paper amid wider regulatory clampdown | ||
| 12:46 | US FDA rejects approval of Unicycive's kidney disease therapy | ||
| 09:46 | Eli Lilly and Innovent agree Verzenios commercialisation deal in China | ||
| Di | Lilly and Regeneron amongst first incumbents to FDA's fast-track facility scheme | ||
| Di | Talawar Therapeutics to debut on Nasdaq with $285m as Dupixent challenger | ||
| Di | Anixa Biosciences secures Korean patent for breast cancer vaccine | ||
| Di | Zymeworks agrees to buy Theravance Biopharma for $929m | ||
| Mo | EMA backs market rollback of rare disease drug Tavneos over data concerns | ||
| Mo | Biogen trims Apellis pipeline and R&D team after $5.6bn takeover | ||
| Mo | FDA issues complete response letter to Sobi's NASP for gout | ||
| Mo | Lilly's Jaypirca receives CHMP positive opinion for CLL in Europe | ||
| Fr | Immunai and Boehringer partner to identify T-cell targets | ||
| Fr | Tryngolza charts blockbuster course after FDA's hypertriglyceridemia approval | ||
| Fr | Lilly-backed Absci banks $100m to progress endometriosis, hair loss therapy | ||
| Fr | Ionis grants Recordati rights to zilganersen for Alexander disease | ||
| Fr | BIO 2026: Former FDA staff question agency's "radical transparency" approach | ||
| Do | Merck KGaA to buy Bio-Techne for $11.3bn in life science footprint expansion | ||
| Do | MSD's Keytruda-Padcev combo secures EC approval for MIBC | ||
| Do | RQ Bio secures $115m to develop influenza antibody programme | ||
| Do | BIO 2026: How NIH cuts have threatened US competitiveness against China | ||
| 24.06. | Novartis targets undruggable cancers with $1.9bn Antares Therapeutics deal | ||
| 24.06. | OURA and Lilly join forces to harmonise drug-wearable obesity care |